Exact Sciences (EXAS)
(Delayed Data from NSDQ)
$56.36 USD
-2.46 (-4.18%)
Updated Aug 14, 2024 03:59 PM ET
After-Market: $56.56 +0.20 (0.35%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth F Momentum B VGM
Brokerage Reports
0 items in cart
Exact Sciences Corporation [EXAS]
Reports for Purchase
Showing records 161 - 180 ( 369 total )
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 4th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
1Q15 Preview - Expecting Cologuard Volumes to Easily Top 1Q Guide - Sales Could be Noisy - 2Q Volume Trajectory Key - Warming Slightly - Maintain N
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Healthcare -1Q 2015: Quarterly Medical Technology Trading - Acquisition Valuation Update
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
1Q15 Volume Outlook Light Despite Positive Early Metrics
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
4Q14 Preview - Expecting Healthy Test Ramp - Refining Our Street-High Model Lower for Medicare Advantage, Timing and Precedents - Maintain NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Updating Model - Early Commercial Traction Positive
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Healthcare: 4Q 2014: Quarterly Medical Technology Trading - Acquisition Valuation Update
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Preannouncement Watch - Look for Med Tech News into Next Week?s JPM Conference.
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
3Q14 Recap - Still Early for Sales, But Initial Dr. Sign-ups & Post CMS Order Acceleration Seems Good - Test Compliance Unknown - Maintain N
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 27
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
3Q14 Preview - Early Days for Revenue Collection - Volume Ramp, In-Network Contracting & Opex in Focus - Reaffirm N
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
3Q 2014: Quarterly Medical Technology Trading & Acquisition Valuation Update
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Upping PT to $19 from $14 Post Prelim CMS Pricing Decision
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z